Literature DB >> 33562668

Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications.

Ignacio J Cardona-Benavides1,2, Cristina de Ramón1,2, Norma C Gutiérrez1,2,3.   

Abstract

Some genetic abnormalities of multiple myeloma (MM) detected more than two decades ago remain major prognostic factors. In recent years, the introduction of cutting-edge genomic methodologies has enabled the extensive deciphering of genomic events in MM. Although none of the alterations newly discovered have significantly improved the stratification of the outcome of patients with MM, some of them, point mutations in particular, are promising targets for the development of personalized medicine. This review summarizes the main genetic abnormalities described in MM together with their prognostic impact, and the therapeutic approaches potentially aimed at abrogating the undesirable pathogenic effect of each alteration.

Entities:  

Keywords:  chromosomal translocations; copy number changes; multiple myeloma; point mutations; prognosis; targeted therapy

Year:  2021        PMID: 33562668      PMCID: PMC7914805          DOI: 10.3390/cells10020336

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  197 in total

1.  Clinical impact of chromothriptic complex chromosomal rearrangements in newly diagnosed multiple myeloma.

Authors:  Gurvinder Kaur; Ritu Gupta; Nitin Mathur; Lata Rani; Lalit Kumar; Atul Sharma; Vishwajeet Singh; Anubha Gupta; Om Dutt Sharma
Journal:  Leuk Res       Date:  2018-12-15       Impact factor: 3.156

2.  BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma.

Authors:  Eileen M Boyle; Cody Ashby; Ruslana G Tytarenko; Shayu Deshpande; Hongwei Wang; Yan Wang; Adam Rosenthal; Jeffrey Sawyer; Erming Tian; Erin Flynt; Antje Hoering; Sarah K Johnson; Michael W Rutherford; Christopher P Wardell; Michael A Bauer; Charles Dumontet; Thierry Facon; Sharmilan Thanendrarajan; Carolina D Schinke; Maurizio Zangari; Frits van Rhee; Bart Barlogie; David Cairns; Graham Jackson; Anjan Thakurta; Faith E Davies; Gareth J Morgan; Brian A Walker
Journal:  Clin Cancer Res       Date:  2020-01-27       Impact factor: 12.531

3.  Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management

Authors: 
Journal:  Am J Hematol       Date:  2018-08-16       Impact factor: 10.047

4.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.

Authors:  Joseph R Mikhael; David Dingli; Vivek Roy; Craig B Reeder; Francis K Buadi; Suzanne R Hayman; Angela Dispenzieri; Rafael Fonseca; Taimur Sher; Robert A Kyle; Yi Lin; Stephen J Russell; Shaji Kumar; P Leif Bergsagel; Steven R Zeldenrust; Nelson Leung; Matthew T Drake; Prashant Kapoor; Stephen M Ansell; Thomas E Witzig; John A Lust; Robert J Dalton; Morie A Gertz; A Keith Stewart; Keith Stewart; S Vincent Rajkumar; Asher Chanan-Khan; Martha Q Lacy
Journal:  Mayo Clin Proc       Date:  2013-04       Impact factor: 7.616

5.  Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients.

Authors:  Florence Magrangeas; Hervé Avet-Loiseau; Nikhil C Munshi; Stéphane Minvielle
Journal:  Blood       Date:  2011-05-31       Impact factor: 22.113

6.  A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression.

Authors:  Christina M Annunziata; Lidia Hernandez; R Eric Davis; Adriana Zingone; Laurence Lamy; Lloyd T Lam; Elaine M Hurt; Arthur L Shaffer; W Michael Kuehl; Louis M Staudt
Journal:  Blood       Date:  2010-12-16       Impact factor: 22.113

7.  Prognostic impact of hyperdiploidy in multiple myeloma patients with high-risk cytogenetics: a pilot study in China.

Authors:  Jiangang Mei; Yongping Zhai; Hanqing Li; Feng Li; Xiaogang Zhou; Ping Song; Qian Zhao; Yaping Yu; Zhiming An; Liping Wang
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-24       Impact factor: 4.553

8.  Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma.

Authors:  W-J Chng; G F Huang; T H Chung; S B Ng; N Gonzalez-Paz; T Troska-Price; G Mulligan; M Chesi; P L Bergsagel; R Fonseca
Journal:  Leukemia       Date:  2011-04-05       Impact factor: 11.528

9.  First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.

Authors:  Alessandra Larocca; Roberto Mina; Massimo Offidani; Anna Marina Liberati; Antonio Ledda; Francesca Patriarca; Andrea Evangelista; Stefano Spada; Giulia Benevolo; Daniela Oddolo; Vanessa Innao; Clotilde Cangiolosi; Annalisa Bernardini; Pellegrino Musto; Valeria Amico; Vincenzo Fraticelli; Laura Paris; Nicola Giuliani; Antonietta Pia Falcone; Renato Zambello; Lorenzo De Paoli; Alessandra Romano; Antonio Palumbo; Vittorio Montefusco; Roman Hájek; Mario Boccadoro; Sara Bringhen
Journal:  Haematologica       Date:  2019-06-27       Impact factor: 9.941

10.  Deletions of CDKN2C in multiple myeloma: biological and clinical implications.

Authors:  Paola E Leone; Brian A Walker; Matthew W Jenner; Laura Chiecchio; Gianpaolo Dagrada; Rebecca K M Protheroe; David C Johnson; Nicholas J Dickens; Jose Luis Brito; Monica Else; David Gonzalez; Fiona M Ross; Selina Chen-Kiang; Faith E Davies; Gareth J Morgan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

View more
  15 in total

Review 1.  Multiple Myeloma: Molecular Pathogenesis and Disease Evolution.

Authors:  Michael Heider; Katharina Nickel; Marion Högner; Florian Bassermann
Journal:  Oncol Res Treat       Date:  2021-11-08       Impact factor: 2.825

2.  Conventional Karyotyping and Fluorescence In Situ Hybridization for Detection of Chromosomal Abnormalities in Multiple Myeloma.

Authors:  Matthew Crabtree; Jennifer Cai; Xin Qing
Journal:  J Hematol       Date:  2022-06-27

3.  BoBafit : A copy number clustering tool designed to refit and recalibrate the baseline region of tumors' profiles.

Authors:  G Mazzocchetti; A Poletti; V Solli; E Borsi; M Martello; I Vigliotta; S Armuzzi; B Taurisano; E Zamagni; M Cavo; C Terragna
Journal:  Comput Struct Biotechnol J       Date:  2022-07-03       Impact factor: 6.155

4.  Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones.

Authors:  Libere J Ndacayisaba; Kate E Rappard; Stephanie N Shishido; Carmen Ruiz Velasco; Nicholas Matsumoto; Rafael Navarez; Guilin Tang; Pei Lin; Sonia M Setayesh; Amin Naghdloo; Ching-Ju Hsu; Carlisle Maney; David Symer; Kelly Bethel; Kevin Kelly; Akil Merchant; Robert Orlowski; James Hicks; Jeremy Mason; Elisabeth E Manasanch; Peter Kuhn
Journal:  Curr Oncol       Date:  2022-04-21       Impact factor: 3.109

5.  YTHDF2 promotes multiple myeloma cell proliferation via STAT5A/MAP2K2/p-ERK axis.

Authors:  Zhen Hua; Rongfang Wei; Mengjie Guo; Zigen Lin; Xichao Yu; Xinying Li; Chunyan Gu; Ye Yang
Journal:  Oncogene       Date:  2022-01-24       Impact factor: 8.756

6.  The Dynamics of Nucleotide Variants in the Progression from Low-Intermediate Myeloma Precursor Conditions to Multiple Myeloma: Studying Serial Samples with a Targeted Sequencing Approach.

Authors:  Bénedith Oben; Charlotte Cosemans; Ellen Geerdens; Loes Linsen; Kimberly Vanhees; Brigitte Maes; Koen Theunissen; Bert Cruys; Marta Lionetti; Ingrid Arijs; Niccolò Bolli; Guy Froyen; Jean-Luc Rummens
Journal:  Cancers (Basel)       Date:  2022-02-18       Impact factor: 6.639

7.  Study on the Relationship Between the Expression of B Cell Mature Antigen and the Classification, Stage, and Prognostic Factors of Multiple Myeloma.

Authors:  Tiantian Ma; Jing Shi; Yuxia Xiao; Tianyue Bian; Jincheng Wang; Lingyun Hui; Mengchang Wang; Huasheng Liu
Journal:  Front Immunol       Date:  2021-11-18       Impact factor: 7.561

Review 8.  The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications.

Authors:  Anna Puła; Paweł Robak; Damian Mikulski; Tadeusz Robak
Journal:  Int J Mol Sci       Date:  2021-11-08       Impact factor: 5.923

9.  Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers.

Authors:  Virág Réka Szita; Gábor Mikala; András Kozma; János Fábián; Apor Hardi; Hussain Alizadeh; Péter Rajnics; László Rejtő; Tamás Szendrei; László Váróczy; Zsolt Nagy; Árpád Illés; István Vályi-Nagy; Tamás Masszi; Gergely Varga
Journal:  Pathol Oncol Res       Date:  2022-02-28       Impact factor: 3.201

Review 10.  Novel Psychoactive Substances: The Razor's Edge between Therapeutical Potential and Psychoactive Recreational Misuse.

Authors:  Beatriz Correia; Joana Fernandes; Maria João Botica; Carla Ferreira; Alexandre Quintas
Journal:  Medicines (Basel)       Date:  2022-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.